# A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease

> **NCT01526785** · PHASE4 · TERMINATED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 113 (actual)

## Conditions studied

- Pompe Disease

## Interventions

- **DRUG:** Alglucosidase alfa

## Key facts

- **NCT ID:** NCT01526785
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-03
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 113 (ACTUAL)
- **Why stopped:** Terminated due to approved label expansion
- **Last updated:** 2015-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01526785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01526785, "A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT01526785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*